Venator

Photo
22.05.2023 • News

Venator in US Chapter 11 Bankruptcy Proceedings

Venator, the Huntsman spinoff that holds the family-owned business’s former titanium dioxide activities, has filed for protection from creditors under the US Chapter 11 bankruptcy code.

Photo
16.01.2023 • News

Venator Investor Seeks Urgent Board Change

Venator’s second-largest investor, Czech private equity fund J&T MS 1 SICAV, is asking for a seat on the board of the UK-headquartered multinational pigments and additives producer, citing major concerns about its financial underperformance and massive shareholder value destruction.

Photo
18.11.2022 • News

Venator Sells Iron Oxide Pigments to Cathay Industries

US titanium dioxide pigments and performance additives producer Venator Materials has agreed to sell its iron oxide business to Hong Kong’s Cathay Industries for an enterprise value of $140 million. The transaction is expected to close by the end of quarter one 2023.

Photo
11.04.2022 • News

Venator Wins Lawsuit against Tronox

Venator Materials has won a $75 million lawsuit against Tronox in a case over a break fee contained in an exclusivity agreement entered into in July 2018 relating to the latter’s merger with Cristal.

Photo
03.09.2020 • News

Huntsman Sells Venator Shares to SK Capital

Huntsman has agreed to sell about 42.5 million shares in Venator Materials – representing just below 40% of Venator’s outstanding shares – to private equity group SK Capital Partners for $100 million cash. The deal includes a 30-month option at $2.15/share for the remaining 9.5 million shares that Huntsman owns.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.